ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1886

Continued Fracture Risk Reduction after 12 Months of Romosozumab Followed By Denosumab through 36 Months in the Extension of the Phase 3 Fracture Study in Postmenopausal Women with Osteoporosis

E Michael Lewiecki1, Rajani V Dinavahi2, Marise Lazaretti-Castro3, Peter R Ebeling4, J Adachi5, Akimitsu Miyauchi6, Evelien Gielen7, Cassandra E Milmont2, Cesar Libanati8 and Andreas Grauer2, 1New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, 2Amgen Inc., Thousand Oaks, CA, 3Federal University of São Paulo, São Paulo, Brazil, 4Monash University, Melbourne, Australia, 5McMaster University, Hamilton, ON, Canada, 6Miyauchi Medical Center, Osaka, Japan, 7University Hospitals Leuven, Leuven, Belgium, 8UCB Pharma, Brussels, Belgium

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Bone density, clinical trials, denosumab, fractures and osteoporosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Romosozumab (Romo) is a monoclonal antibody that binds sclerostin with a dual effect, increasing bone formation and decreasing bone resorption. In the primary analysis of the multicenter, double-blind, FRActure study in postmenopausal woMen with ostEoporosis (FRAME) (NCT01575834), women aged 55–90 (T-score ≤–2.5 at total hip [TH] or femoral neck), Romo significantly reduced vertebral and clinical fracture risk vs placebo (Pbo) at 12 months (M).1 A continued 75% new vertebral fracture and 33% clinical fracture relative risk reduction was observed at 24M in patients who initially received Romo, despite all patients receiving denosumab (DMAb) after 12M. BMD showed rapid and robust increases with Romo at the spine and hip, and these increases continued on transition to DMAb.1

Methods: In FRAME, patients received Pbo or Romo SC monthly for 12M, followed by open-label DMAb SC every 6M for 12M. Here, we report results through 36M after a further 12M of open-label DMAb. Key endpoints included patient incidence of new vertebral, clinical (nonvertebral plus symptomatic vertebral), and nonvertebral fracture, and BMD.

Results: Of the 7180 women enrolled, 5743 (80%) completed the 36M study (2892 Pbo followed by DMAb; 2851 Romo followed by DMAb). Through 36M, fracture risk reduction was observed for new vertebral, clinical, nonvertebral, and other predefined fracture endpoints in patients who received Romo followed by 24M of DMAb vs Pbo followed by 24M of DMAb (Table). At 36M, BMD continued to increase in the Romo followed by DMAb group to 18.1% (lumbar spine) and 9.4% (TH) (Figure). The mean differences in BMD in patients who received Romo in the first 12M compared with those initially on Pbo remained significant over the entire 36M (P<0.001). Adverse events were generally balanced between groups; no additional positively adjudicated cases of atypical femoral fracture or osteonecrosis of the jaw were reported since reporting the 24M data.1

Conclusion: In postmenopausal women with osteoporosis, Romo followed by DMAb was well tolerated and reduced new vertebral, clinical, and nonvertebral fracture risk vs Pbo followed by DMAb for 24M. BMD continued to increase in both groups. BMD in patients treated with Romo in the first 12M remained significantly higher than in those who initially received Pbo despite all patients receiving DMAb for 24M, underscoring the important foundational effect of Romo. The sequence of Romo followed by DMAb will be a promising treatment regimen for postmenopausal women with osteoporosis.

1Cosman NEJM 2016


Disclosure: E. M. Lewiecki, Amgen, 2,Amgen, Radius, 5; R. V. Dinavahi, Amgen, 1,Amgen, 3; M. Lazaretti-Castro, Amgen, Eli Lilly, Merck, 2,Amgen, Eli Lilly, Sanofi, 5; P. R. Ebeling, Amgen, Eli Lilly, UCB, 5,Amgen, Eli Lilly, 8; J. Adachi, Amgen, Eli Lilly, Merck, 2,Amgen, Eli Lilly, Merck, 5,International Osteoporosis Foundation Board of Directors, Scientific Advisor; Osteoporosis Canada Past-President, 6,Amgen, 8; A. Miyauchi, Amgen Astellas BioPharma K.K, 5; E. Gielen, Amgen, 8; C. E. Milmont, Amgen, 1,Amgen, 3; C. Libanati, UCB Pharma, 1,UCB Pharma, 3; A. Grauer, Amgen, 1,Amgen, 3.

To cite this abstract in AMA style:

Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, Ebeling PR, Adachi J, Miyauchi A, Gielen E, Milmont CE, Libanati C, Grauer A. Continued Fracture Risk Reduction after 12 Months of Romosozumab Followed By Denosumab through 36 Months in the Extension of the Phase 3 Fracture Study in Postmenopausal Women with Osteoporosis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/continued-fracture-risk-reduction-after-12-months-of-romosozumab-followed-by-denosumab-through-36-months-in-the-extension-of-the-phase-3-fracture-study-in-postmenopausal-women-with-osteoporosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/continued-fracture-risk-reduction-after-12-months-of-romosozumab-followed-by-denosumab-through-36-months-in-the-extension-of-the-phase-3-fracture-study-in-postmenopausal-women-with-osteoporosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology